Cargando…
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Type 2 diabetes is a metabolic, chronic disorder characterized by insulin resistance and elevated blood glucose levels. Although a large drug portfolio exists to keep the blood glucose levels under control, these medications are not without side effects. More importantly, once diagnosed diabetes is...
Autores principales: | Demir, Sevgican, Nawroth, Peter P., Herzig, Stephan, Ekim Üstünel, Bilgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456215/ https://www.ncbi.nlm.nih.gov/pubmed/34319011 http://dx.doi.org/10.1002/advs.202100275 |
Ejemplares similares
-
TSC22D4 interacts with Akt1 to regulate glucose metabolism
por: Demir, Sevgican, et al.
Publicado: (2022) -
Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention
por: Brings, Sebastian, et al.
Publicado: (2017) -
Control of diabetic hyperglycaemia and insulin resistance through TSC22D4
por: Ekim Üstünel, Bilgen, et al.
Publicado: (2016) -
Diabetic Pneumopathy–A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations
por: Kopf, Stefan, et al.
Publicado: (2021) -
Lipocalin 13 enhances insulin secretion but is dispensable for systemic metabolic control
por: Bühler, Lea, et al.
Publicado: (2021)